4.4 Editorial Material

The Early Diagnosis of Alzheimer's Disease: A Patient-Centred Conversation with the Care Team

期刊

NEUROLOGY AND THERAPY
卷 12, 期 1, 页码 11-23

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s40120-022-00428-7

关键词

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Early diagnosis; Neuroimaging; Patient management; Psychological impact of biomarker testing

向作者/读者索取更多资源

Alzheimer's disease (AD), the leading cause of dementia, affects around 10 million people in Europe. Early diagnosis of AD can be achieved through neuroimaging techniques and biomarkers, but challenges such as low sensitivity, high cost, and limited availability need to be addressed. Plasma biomarkers offer a low-cost and non-invasive alternative for AD screening and diagnosis. In addition to technical challenges, organizational and ethical concerns must also be taken into account for effective diagnosis and patient care.
Alzheimer's disease (AD) is a neurodegenerative disorder which accounts for 60-80% of dementia cases, affecting approximately 10 million people in Europe. Neuroimaging techniques and cerebrospinal fluid biomarkers used in combination with cognitive assessment tools open the door to early diagnosis of AD. However, these tools present some challenges that need to be overcome, such as low sensitivity or specificity, high cost, limited availability or invasiveness. Thus, low-cost and non-invasive alternatives, such as plasma biomarkers, have the potential to drive changes in AD screening and diagnosis. In addition to the technical aspects, organisational challenges as well as ethical concerns need to be addressed. In many countries, there is an insufficient number of specialists to recognise, evaluate and diagnose dementia and the waiting times to see a specialist are long. Given that there is currently no cure for AD, it is important to consider the potential psychological impact of an early diagnosis. In addition, counselling before biomarker sampling and during diagnosis disclosure is vital to guarantee that the patients have all the information necessary and their queries are addressed in a sensitive manner. Here, we illustrate (using a clinical vignette) current challenges of diagnosis and discuss some of the benefits and challenges of early diagnosis in AD including the value of biomarkers in combination with clinical evaluation. Lastly, some guidelines for disclosing early diagnosis of AD are provided based on our experiences.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据